The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Authors :: Wiederhold NP
Najvar LK
Fothergill AW
McCarthy DI
Bocanegra R
Olivo M
Kirkpatrick WR
Everson MP
Duncanson FP
Patterson TF
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Jan; Vol. 59 (1), pp. 690-2. Date of Electronic Publication: 2014 Oct 20.
Publication Year :: 2015
Abstract: The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.<br /> (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)

Full Text Access

Tools